Presidio Capital Management LLC Acquires Shares of 7,992 Edwards Lifesciences Co. (NYSE:EW)

Presidio Capital Management LLC bought a new position in Edwards Lifesciences Co. (NYSE:EW) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 7,992 shares of the medical research company’s stock, valued at approximately $527,000.

Other hedge funds have also made changes to their positions in the company. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $28,000. First Community Trust NA bought a new position in Edwards Lifesciences in the 2nd quarter valued at $29,000. Webster Bank N. A. acquired a new position in Edwards Lifesciences in the second quarter worth $39,000. Peoples Bank KS bought a new stake in shares of Edwards Lifesciences during the third quarter worth $40,000. Finally, Versant Capital Management Inc increased its stake in shares of Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after buying an additional 326 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

EW opened at $65.84 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The company has a market capitalization of $39.66 billion, a price-to-earnings ratio of 9.50, a P/E/G ratio of 3.74 and a beta of 1.12. The business’s 50-day moving average price is $67.75 and its two-hundred day moving average price is $77.18. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.59 EPS. Equities analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on EW. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Wells Fargo & Company lowered their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Barclays decreased their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Finally, Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $75.67.

Insider Activity at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,133,916.72. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,250 shares of company stock valued at $2,746,988. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.